Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAP : NSDQ)

• Company Description    Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. Number of Employees: 506

• Price / Volume Information    Yesterday's Closing Price: $0.06 Daily Weekly Monthly 20 Day Moving Average: 105,943,032 shares Shares Outstanding: 265.05 (millions) Market Capitalization: $15.64 (millions) Beta: 2.49 52 Week High: $0.86 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -64.75% -64.97% 12 Week -41.00% -44.03% Year To Date -89.05% -90.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 JUBILEE AVENUE MILTON PARK - ABINGDON,X0 OX14 4RX GBR ph: 44-12-3543-0000 fax: 44-12-3543-0001 ir@adaptimmune.com http://www.adaptimmune.com

• General Corporate Information    Officers Adrian Rawcliffe - Chief Executive Officer and Director David M. Mott - Chairman of the Board of Director William Bertrand - Chief Operating Officer Gavin Wood - Chief Financial Officer Andrew Allen - Director Peer Information Adaptimmune Therapeutics PLC (CORR.) Adaptimmune Therapeutics PLC (RSPI) Adaptimmune Therapeutics PLC (CGXP) Adaptimmune Therapeutics PLC (BGEN) Adaptimmune Therapeutics PLC (GTBP) Adaptimmune Therapeutics PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00653A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 265.05 Most Recent Split Date: (:1) Beta: 2.49 Market Capitalization: $15.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.24 EPS Growth vs. Year Ago Period: -140.74% vs. Previous Quarter: 38.89% Sales Growth vs. Year Ago Period: -89.33% vs. Previous Quarter: 87.74% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - -163.73 ROA 09/30/25 - - 06/30/25 - -75.83 03/31/25 - -23.65 Current Ratio 09/30/25 - - 06/30/25 - 1.52 03/31/25 - 2.02 Quick Ratio 09/30/25 - - 06/30/25 - 1.29 03/31/25 - 1.79 Operating Margin 09/30/25 - - 06/30/25 - -248.20 03/31/25 - -34.33 Net Margin 09/30/25 - - 06/30/25 - -260.82 03/31/25 - -38.91 Pre-Tax Margin 09/30/25 - - 06/30/25 - -255.12 03/31/25 - -36.89 Book Value 09/30/25 - - 06/30/25 - -0.27 03/31/25 - -0.15 Inventory Turnover 09/30/25 - - 06/30/25 - 0.43 03/31/25 - 0.18 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©